Is Zolbetuximab-Vyloy an injection? What is the usage

Zolbetuximab-Vyloy is a monoclonal antibody targeting Claudin 18.2 (CLDN18.2), specifically used to treat advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. As a targeted therapy, it blocks the growth signals of tumor cells by binding to the CLDN18.2 protein, while activating the immune system to eliminate cancer cells. For many gastric cancer patients, this drug brings new treatment hope. So, how is zotuximab administered? Is it an injectable preparation?

The answer is yes. Zotuximab is an injection preparation for intravenous infusion, and its administration method is intravenous drip (IV infusion). Usually, the drug needs to be prepared by professional medical staff in a hospital or professional medical institution and infused slowly to ensure that the drug can enter the body evenly and reduce the occurrence of adverse reactions. Vyloy is typically not administered orally or otherwise, but rather as an intermittent intravenous infusion, and is used in combination with standard chemotherapy, such as fluoropyrimidine- and platinum-based chemotherapy regimens, to enhance the anti-cancer effect.

Before using Vyloy, patients usually need to receive pretreatment with antiemetic drugs to reduce possible adverse reactions such as nausea and vomiting during treatment. The first infusion usually takes a long time, and medical staff will closely monitor the patient for allergic or infusion-related reactions, such as hypotension, chills, or skin itching. Subsequent infusion times may be shortened but still need to be performed in a medical setting to ensure safety.

In general, zotuximab is an injectable preparation, and its standard administration method is intravenous infusion. When patients receive treatment, they need to be under the guidance of a doctor to ensure safety and therapeutic effect. For patients who plan to use Vyloy, it is recommended to communicate with a professional doctor to learn more about the infusion plan and possible adverse reactions to obtain the best treatment experience.

Reference: https://en.wikipedia.org/wiki/Zolbetuximab